Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in accordance with supplementary material requirements and will disclose key information as per legal obligations [1] Group 1: Company Developments - The company is actively contributing to the macroeconomic strategy addressing population aging, focusing on traditional Chinese medicine [1] - Kangyuan has core products targeting health needs of the elderly, including treatments for cardiovascular diseases and bone injuries, such as Ginkgo Biloba Diterpene Injection and Tian Shu Capsules [1] - The company is also developing treatments for Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with related products entering clinical stages [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported revenue of 2.343 billion yuan, a year-on-year decrease of 24.59% (adjusted) [1] - The net profit attributable to the parent company was 200 million yuan, reflecting a year-on-year decline of 35.63% [1]

Core Viewpoint - Samsung Medical is committed to advancing its digital transformation strategy to enhance patient experience and medical quality amid the aging population in China [1] Group 1: Financial Performance - For the period from January to September, Samsung Medical achieved a revenue of 11.08 billion yuan, representing a year-on-year growth of 6.19% [1] - The company reported a net profit attributable to shareholders of 1.528 billion yuan, which reflects a year-on-year decline of 15.85% [1] Group 2: Strategic Focus - The company is focusing on chain operations, discipline construction, and medical quality to deepen its engagement in the rehabilitation sector [1] - Continuous improvement in management and operational levels is a priority for the company [1]

按2024年收益计，公司在中国医药营销推广销售市场排名前十，是中国最大的儿科医药营销推广销售服 务供应商，份额约15.9%。其销售网络遍布内地31个省份，截至2025年6月30日，拥有超1500家分销 商，覆盖众多诊所、药房和医院。 近日，据港交所官网显示，科郦有限公司向港交所主板递交上市申请，中金公司为独家保荐人。 该公司致力于以数字方案推动医药供应链升级，促进生物健康与营养领域创新。其业务涵盖医药营销推 广销售，以及母婴及营养补充品研发生产分销。 (编辑：杨燕 林辰) （港交所官网披露易） ...

12月19日，周大福对部分黄金、铂金及铂金镶钻等产品提价。公开信息显示，以古法金、故宫联名系列 为例，大部分商品涨幅集中在4%-16%之间。 对于此次调价，周大福表示，"产品价格调整属集团的日常营运政策，我们会根据市场环境及产品需 求，适时作出调价，并始终坚持维护卓越品质与精湛工艺的承诺，满足消费者的期待。" 据梳理，2025年3月、10月底及12月，周大福已累计三次上调产品价格。前两次调价幅度分别为 10%-20%、12%-18%。 (周大福) ...

12月19日，百济神州发布公告称，经百济神州有限公司（以下简称"公司"）董事会审议通过，公司董事 会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。聘任生效后，汪来博士担任 公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等职能。 (编辑：杨燕 林辰)关键字： 医疗 公告显示，汪来自2021年4月起担任公司全球研发负责人。在此之前，自2011年加入公司以来，他担任 过多个研发领导职务，职责逐渐扩大加入公司之前，于2008 年至2011年，汪来在位于美国德克萨斯州 达拉斯的生物技术公司 Joyant Pharmaceuticals 担任研究主管。汪来于1996年获得复旦大学理学学士学 位，于2001年获得德克萨斯大学圣安东尼奥健康科学中心博士学位。 （百济神州公告） ...

Core Insights - Galaxy General Robotics has completed a new financing round exceeding $300 million (approximately 2.1 billion RMB) [1] - The company's valuation has reached $3 billion (approximately 21.1 billion RMB) [1] Financing Details - The financing round was led by China Mobile's Chain Long Fund, with participation from CITIC Capital, the Chinese Academy of Sciences Fund, Suzhou Venture Capital, CCTV Media Fund, and Tianqi Co., Ltd. [1] - International investment institutions from Singapore and the Middle East, along with existing shareholders, also contributed to the funding [1] Use of Funds - The funds raised will be utilized for breakthroughs in core technology related to the embodied large model, industrialization, and global expansion [1]

12月18日，北京市人民政府新闻办公室举行北京培育建设国际消费中心城市工作成效和亮点新闻发布 会。 文旅消费已成为推动国际消费中心城市建设的重要增长极。 北京市文化和旅游局党组成员、副局长徐振涛表示，市文化和旅游局深入贯彻落实《北京市培育建设国 际消费中心城市实施方案》，持续激发文旅消费潜力、提升消费品质。截至今年1—10月，全市接待游 客总量超过3亿人次，旅游花费超过6000亿元，同比分别增长5.4%和7.2%，文旅消费已成为推动国际消 费中心城市建设的重要增长极。 ...

据悉，万象天地商业综合体位于长风街太原广场，建筑面积约44.5万平方米，将采用"街区+盒子 MALL"相融合的创新模式，由华润万象生活整体运营，上海天华集团旗下AICO设计团队操刀设计，汇 聚国际奢侈品牌、高端餐饮及文化艺术空间等多元业态，包含溪谷广场、山涧飞瀑、游山之径、四季山 庭等特色空间，商业场景丰富多元。 （小店发布） 建筑面积约44.5万平方米 12月15日，太原广场和华润万象生活合作签约仪式举行，华北地区首座万象天地正式落户太原市小店 区。 ...

Core Viewpoint - Xidi Intelligent Driving (03881.HK) has officially listed on the Hong Kong Stock Exchange, becoming the first publicly traded company in Hong Kong focused on intelligent driving for commercial vehicles [1] Group 1: Company Overview - Xidi Intelligent Driving issued a total of 5.40798 million shares at a price of HKD 263 per share, resulting in a market capitalization of HKD 11.5 billion and total fundraising of HKD 1.422 billion [1] - The company specializes in the research and development of autonomous trucks for closed environments (such as mines and logistics parks), V2X (Vehicle-to-Everything) technology, and intelligent perception solutions [1] Group 2: Financial Performance - According to the prospectus, Xidi Intelligent Driving's revenue is projected to be HKD 31 million, HKD 133 million, and HKD 410 million for the years 2022, 2023, and 2024, respectively, with a compound annual growth rate of 263.1% [2] - The adjusted net losses are expected to decrease from HKD 159 million in 2022 to HKD 127 million in 2024, indicating a continuous narrowing trend [2] - The gross margin is projected to improve from -19.3% to 24.7% over the same period [2] - In the first half of 2025, the company's revenue is expected to grow by 57.9% year-on-year to HKD 408 million, marking a steady transition into the commercial monetization phase [2] Group 3: Strategic Vision - The founder and chairman of Xidi Intelligent Driving, Li Zexiang, emphasized the company's mission to reshape human transportation experiences and boundaries through core technology, aiming to make intelligent driving technology truly serve humanity [1] - The company aims to accelerate the large-scale implementation of intelligent driving technology for commercial vehicles, creating long-term sustainable value for shareholders and contributing to a safer, more efficient, and comfortable green intelligent transportation ecosystem [1]

12月18日，捷尼赛思宣布，任命Sean Lee 为捷尼赛思全球负责人，同时，Sean Lee 将于2026年1月1日晋 升为高级副总裁。Sean Lee 在现代汽车集团拥有25年的汽车行业经验，2017年8月，Sean Lee 正式加入 捷尼赛思，负责产品规划与运营管理。 ...